News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Download Now: New Slide Deck Programme
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
AHA Scientific Sessions 2019
16-18 November, Philadelphia, USA
ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
ORION-10: effective LDL-C lowering in patients with ASCVD with twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI
ESC Congress 2019 with World Congress of Cardiology
EVOPACS: Evolocumab in acute ACS
ORION-11 with inclisiran
LDL cholesterol goals go lower…
Hot Topics
News from the 11th Expert Meeting of the Editorial Board of PCSK9 Forum
LDL transcytosis in atherosclerosis: Professor Phil Shaul (Center for Pulmonary and Vascular Biology, University of Texas Southwestern Medical Center, Dallas, USA)
Emerging lipid science – Apolipoprotein E and chronic disease: Professor Ruth Frikke-Schmidt (Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark) discusses exciting research
From the Editors
Are we doing any better with familial hypercholesterolaemia care?
Professor Eric Bruckert, Pitié-Salpêtrière Hospital, Paris, France
Has the care of this common inherited disorder, characterised by high cholesterol levels from birth, improved in the last 5 years? What can we learn from the only global registry?
Read the report
Insights from the EAS FHSC Registry, Prof. Eric Bruckert
Watch the video
Too little, too late: Prof. Raul Santos discusses the EAS FHSC Registry data
Watch the video
2019 ESC/EAS Dyslipidaemia Guidelines and FH, Prof. Eric Bruckert
Watch the video
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
